TScan Therapeutics Inc TCRX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-16 |
| Shares Out. | 65,350,000 |
| Website | tscan.com ↗ |
| Phone | 13025310855 |
| Employees | 142 |
| Revenue | $982,000 |
| Gross Profit | $982,000 |
| Net Income | -$28.7M |
| Free Cash Flow | -$125.0M |
| Total Assets | $202.0M |
| Total Liabilities | $105.1M |
| Equity | $96.9M |
About TScan Therapeutics Inc
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
TScan Therapeutics Inc is a publicly traded company under the ticker symbol TCRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)